Physician profile
Mark Rowand
NPI 1104948702
$6,926.34
in general payments reported to CMS, 2019-2025
50 companies · $914 in 2025
The $914 reported for 2025 was more than what 89% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $1,002 · 2021: $1,166 · 2022: $1,081 · 2023: $1,027 · 2024: $1,083 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,009 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,009.07 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $957.64 | 2021-2025 | Vraylar, Linzess, Qulipta |
| Glaxosmithkline, LLC. | $922.52 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $796.45 | 2019-2025 | |
| Novo Nordisk INC | $668.94 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $344.41 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $327.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $268.25 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $210.21 | 2020-2024 | Evenity, Prolia, Otezla |
| Amarin Pharma, INC. | $203.42 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.57 | 2019-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.48 | 2019-2023 | Jardiance |
| Abbott Laboratories | $166.35 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $147.16 | 2019-2025 | Veozah |
| Allergan, INC. | $138.60 | 2020 | |
| Phathom Pharmaceuticals, INC. | $112.38 | 2024-2025 | Voquezna |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rowand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.